Anti-Amyloid Beta Antibody (CNTO 2125) is a recombinant humanized monoclonal antibody targeting human Amyloid Beta (Abeta/Amyloid Beta). Abeta is the core component of amyloid plaques in the Alzheimers disease (AD) brain, generated from the cleavage of amyloid precursor protein (APP). CNTO 2125 specifically binds to Abeta with high affinity (e.g., EC50 ~ 9.7 ng/mL), blocking the aggregation of Abeta monomers and promoting the clearance of existing plaques. By targeting the Abeta cascade, this antibody has the potential to protect neurons from Abeta-mediated neurotoxic damage, serving as a critical tool for researching the pathogenesis and immunotherapy of Alzheimers disease. This antibody features a huIgG1 heavy chain and a hu-kappa light chain.
Target-Kategorie:
Beta Amyloid
T9901A-1347
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
